Cindy M. Pabon, Assistant Professor of Gastrointestinal Medical Oncology at The University of Miami Sylvester Comprehensive Cancer Center, posted on X:
“Xuefeng Leng presents neoadjuvant chemoRT with/without sintilimab for ESCC. Statistically significant improvement in pCR rates…but is this similar to the reduction in disease we see with CHECKMATE-577? Will need long term survival data for both studies to see if sequence matters.”
